Vericel Corp. (VCEL)

[realfast95]

the UBS presentation (and May) had 3 panels. MACI, Burn and the third blank.
They are still looking for something.

[TVDirector]

cant' see GERN either

VCEL seems set on cornering burn market, for sure, and getting maci into more OR's and becoming the best choice for such therapy.

listened and read thru yesterday's UBS presentation, and it was pretty obvious that they understand what their bread and butter is...
although an interesting comment about them being the only cel therapy company in the US to have products on the market means they have the expertise to do more...... of what, I wonder.
maybe push their facility, sub, ????

if they want to make product for GERN, fine.
otherwise, nope

[realfast95]

You never know what $BMY would buy.
However for Vericel to buy $GERN, it would be suicidal, for me..

[TVDirector]

designed to get you to their site
so they can pump some other stock.

seen it before.

but if it were truuuuuuuue.....
nahhhh

[realfast95]

2 twitter accounts that is obviously BS said today


Fly On The Wall
? @FlyOnTheWallHQ
1m1 minute ago

Carrot On A Stick_Bristol-Meyers Squibb $BMY Board Of Directors Vote On Vericel Corp $VCEL Acquisition

https://twitter.com/FlyOnTheWallHQ/status/1131591399592226816


A couple of days ago they said


StockWatch
? @StockWatchHQ
May 18

Vericel Corp. $VCEL Board Of Directors Votes YES to Acquire Geron Corp.$GERN, Talks In Menlo Park, CA

https://twitter.com/StockWatchHQ/status/1129904227935907840

[TVDirector]

must be a hell of conference!

jk
PPS continues to wallow

will listen in to see if there's any direction besides down...

GLTA

[TVDirector]

low today 15.56

currently 15.85

where from here?

[TVDirector]

while it appears there's no real reason for it to dive-

it could certainly happen, despite Oppenheimer's 2x from here...
or reiterated positive guidance...
or product acquisition and sales numbers.

haven't checked in a while, but short interest was quite high a while back.
but another poster mentioned institutional holdings are up.

management continues to 'plan' their share sales, which I suppose is expected, but never looks good in terms of insider holdings/trading
but there hasn't been an indication of dilution hanging over our heads from what I recall.

someone is willing, however, to continue selling their shares just over 16.00...

and in this market, bizarreness rules and there ain't no assurances from US leaders to calm fears- so I sure suppose the bottom could fall out and VCEL would accelerate their free-fall despite what looks to be sound fundamentals (at least for them).

good luck.

[realfast95]

If it goes below today's low 15.87. Then we could have a problem Houston.

[TVDirector]

or opening a week premarket down significantly again- AND continuing into the morning trading.

guess I just hate the continued malaise associated with VCEL.
after hitting 21, I really never imagined we'd be trading in 15's again- especially with good news and guidance and upped estimates.

hopefully this is lulling folks to sleep and then BAM.
or not.

patience grasshoppers.

[realfast95]

same story, but covered by CBS with video of vericel lab

https://cbsaustin.com/news/local/massachusetts-company-growing-san-antonio-babys-skin

Over 1,800 miles away from Jabari Gray, experts in Cambridge, Massachusetts are growing the San Antonio infant's own skin.

"We know that what were doing is very personal. We're taking somebody's cells and were growing them so they can be used to help them treat them," said Dr. Jon Hopper, Chief Medical Officer at Vericel Corporation.

The 4-month-old is being treated at Texas Children's Hospital in Houston. He was born just three pounds, missing large patches of skin throughout his body. His chance of survival was low.

Vericel Corporation, a bio-pharmaceutical company, usually treats burn victims but Texas doctors thought they may be able to help in Jabari's rare case.

"Our job is exactly the same. We're taking skin cells from biopsy, growing them into sheets so the surgeons can then place them back on the patient," said Dr. Hopper.

Experts received a biopsy of the baby's skin a short time ago and already are developing sheets of it.

"They grow and divide making a very thin sheet, about 4-8 cells thick, across the bottom of flask we grow them in," said Dr. Hopper.

The manufacturing associates keep close watch on the cells as they grow.

"We constantly monitoring the health of the cells under the microscope - that's a daily task," said Dr. Hopper.

The skin cells are fed with amino acids, nutrients and other items crucial to keep them alive.

"It's a very labor intensive process and it requires really surgical precision with some of the operations," said Dr. Hopper.

The process takes about 2-3 weeks. The cells are prepared and packaged to be sent out within 48 hours of the surgery.

"Two days before his planned surgery date, that's when the sheets of his skin cells will be prepared so then they can be transported to the hospital the day before his surgery," said Dr. Hopper.

The sheets of skin cells with be flown on an aircraft in a temperature-controlled container to Houston.

[TVDirector]

and I always hate...

closing a day and especially a week at low of the day/week.

irks me to no end.

[TVDirector]

hope you are correct

low volume with the only sustained pps movement being downward, on first blush, certainly doesn't jibe with the promise of a doubler... but who knows.
market is an odd place these days and direction seems to be determined by offhanded tweets and whims.

good luck

[realfast95]

NexoBrid DD - part 3 $MDWD

Mediwound is a public company on the nasdaq.
$4.35 Wednesday close. Market Cap 118m, 27.2m shares
They have a board on iHub. They were not too pleased with this deal.
Earnings May21st

notable analyst coverage
3/25/2019 Oppenheimer Set Price Target Buy $15.00

They won a lawsuit against $TEVA for $12m last year.

$23m in cash and expect to burn $12 in 2019.
So dilution should be soon.

[realfast95]

Report: Vericel to supply Epicel-based grafts for baby born without skin
May 15, 2019 By Fink Densford

https://www.massdevice.com/report-vericel-to-supply-epicel-based-grafts-for-baby-born-without-skin/

Vericel (NSDQ:VCEL) is growing skin grafts using its Epicel product to help a baby born in Texas without skin, according to a recent Boston Business Journal report.

The company said yesterday that it is creating grafts with its Epicel skin replacement product for newborn Ja’bari Gray, who has been in intensive care since being born earlier this year with skin only on his head, according to the report.

Doctors are still unsure as to what is causing Gray’s condition, according to the BBJ, having previously diagnosed the child with epidermolysis bulls, a rare genetic condition that causes the skin to be fragile and blister easily. That diagnosis was later rejected after genetic tests came back negative, according to the report.

The Epicel product, intended for use in treating burns, uses a patient’s own cells to grow dozens of permanent replacement skin grafts over two to three weeks, according to the report. The company is adapting the Epicel product for Gray, and said that it is not frequently used for off-label cases.

Off-label uses of the Epicel product are so rare that Vericel said it hasn’t collected any data on long-term outcomes, according to the BBJ. Chief medical officer Jon Hopper offered that despite the limited info, there have been no negative safety outcomes, with a 90% survival rate among patients who received the grafts.

The company still plans on focusing on Epicel’s ability to treat serious burns, according to the report, and said it is not actively seeking to expand its label to include cases like Gray’s.

Last week, Vericel said that it inked an exclusive U.S. licensing and supply agreement with MediWound (NSDQ:MDWD) for its NexoBrid biological product, and reported first quarter earnings that missed expectations on Wall Street.

[Lunacy_John Galt]

Institutional ownership up to 96% with numerous new large positions since last quarter reporting.

[realfast95]

NexoBrid DD - part 2 - short term for VCEL

Dr Jeremy Goverman

Currently, there are limitations for – well, currently, I can’t use NexoBrid, because it’s not FDA approved yet. That’s the first and foremost. And I think we’ll – and we’ll use it within the trial and I know that we are moving forward in trying to get some continued access usage until that time in which it is FDA approved. So, we will be able to use it hopefully before that time, but there are still indications for us or limitations on size I think with respect to build used on label, which we do not have on label yet.

https://seekingalpha.com/article/4261334-vericel-corporation-vcel-ceo-nick-colangelo-q1-2019-results-earnings-call-transcript?page=11

So after that pre-meeting, is there a good chance this will be put on a fast track?

[realfast95]

NexoBrid DD - part 1 - short term for VCEL


Biomedical Advanced Research and Development Authority (BARDA)
https://www.phe.gov/about/barda/Pages/default.aspx

Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, was established to aid in securing our nation from chemical, biological, radiological, and nuclear (CBRN) threats,..

From Q1 earnings transcript
We anticipate the first NexoBrid sales in the U.S. to come from purchases under existing BARDA contract, which included $16.5 million commitment for cerement of NexoBrid, contingent upon FDA eligibility for use in an emergency or FDA marketing approval.

Since MediWound holds the BARDA contracts, they will supply the product to BARDA. And we will participate via a proper channel formula, which you deal to Vericel approximately $6 million in revenue with no associated cost of goods. BARDA has not yet placed an order, and therefore, we are not including any procurement revenue in our 2019 revenue guidance. Once an order is placed, we would expect it to be filled over the course of 4to 6 quarters. We will update our 2019 revenue guidance as appropriate when we gain clarity on the timing of BARDA procurement orders. Longer term, BARDA has the option to make up to $50 million of additional NexoBrid purchases, which could yield up to $25 million in profit sharing for Vericel over approximately 10 years.

https://seekingalpha.com/article/4261334-vericel-corporation-vcel-ceo-nick-colangelo-q1-2019-results-earnings-call-transcript?page=6

I found it very enlightening that he is talking about 2019 guidance
when the quickest for FDA approval is 2020.

The pre-BLA meeting is planned for later this quarter, at which time we’ll have additional clarity on the BLA submission timelines.
https://seekingalpha.com/article/4261334-vericel-corporation-vcel-ceo-nick-colangelo-q1-2019-results-earnings-call-transcript?page=7

[realfast95]

Oppenheimer gets it.
My guess is that they see NexoBrid moving faster than advertised.

[TVDirector]

gotta wonder

was there something 'else' behind Oppenheimers upping of target?
it seems a no-brainer, then, if they're right... easy doubleish from these levels.

yet here we wallow....

[realfast95]

Tue - 13:34 Vericel analyst commentary at Oppenheimer Vericel price target raised to $32 from $23 at Oppenheimer. Oppenheimer analyst Kevin Degeeter raised his price target on Vericel (VCEL) to $32 from $23 after the company reported Q1 results, raised its 2019 revenue guidance and announced a deal to license North American rights for NexoBrid from MediWound (WDWD). He keeps an Outperform rating on Vericel shares.

Read more at:
https://thefly.com/landingPageNews.php?id=2904971

[realfast95]

Vericel looks to market a gel for burns with new $142M licensing deal

https://www.bizjournals.com/boston/news/2019/05/07/vericel-looks-to-market-a-gel-for-burns-with-new.html?ana=twt

Cambridge-based cell therapy firm Vericel Corp. has forged a $142 million deal to license a gel used to help heal burns that made just over $3 million in sales last year at an Israeli company.

Vericel (Nasdaq: VCEL) will pay $17.5 million upfront and up to $125 million in milestones to license and sell the burn repair product NexoBrid from Israeli company MediWound Ltd., it announced Tuesday. The gel uses enzymes to remove burned tissue, with around 93 percent of subjects experiencing complete removal of the damaged tissue in a Phase 3 clinical trial.

It will be Vericel’s first commercial step outside of the two products it purchased from French firm Sanofi in 2014. One of those products, Epicel, is a type of skin graft also intended for burn patients.

Vericel announced the deal Tuesday along with its first quarter financials, which fell short of expectations. Although the company hiked its revenue guidance for the remainder of the year, Vericel’s stock price dropped 6 percent Tuesday, hovering around $17.30 when markets closed.

In an interview, CEO Nick Colangelo told the Business Journal that licensing NexoBrid will allow the company to expand the burn product branch of its business, which he described as “volatile." Colangelo estimated there's a $200 million U.S. market opportunity for MediWound's gel, about twice the size of the market for Epicel.

That's because NexoBrid can be used on a larger portion of the 40,000 burn victims hospitalized in the U.S. annually than Epical, said Colangelo. It also comes with a $16 million purchase order from the federal Biomedical Advanced Research and Development Authority and the possibility of another $50 million order in the next 10 years.

Still, the product has not yet been approved in the U.S., and brought in less than $4 million in sales last year, according to MediWound’s year-end financial report. Colangelo attributed the low sales to MediWound’s small sales force and the NexoBrid label in Europe, which states the gel in must be used in a specialized burn center rather than a standard hospital.

“Quite frankly, it’s a very challenging environment in Europe. It’s common to see products that don’t do quite well in Europe do well in U.S.,” Colangelo said. “It hasn’t performed up to their expectations, but I don’t think that’s representative of the market opportunity here in the U.S.”

MediWound plans to file an application with the FDA in late this year or early next year, according to Colangelo.

Most of Vericel’s growth in recent years has been from its knee cartilage repair product, MACI. Vericel executives raised the company’s 2019 revenue guidance Tuesday based on the expectation that MACI will drive $90 million in sales this year compared to $68 million last year, according to Colangelo.

Revenue from Epicel, meanwhile, dropped 13 percent from the $6 million the company reported in the first quarter of 2018.

[realfast95]

Earnings call transcript available

https://seekingalpha.com/article/4261334-vericel-corporation-vcel-ceo-nick-colangelo-q1-2019-results-earnings-call-transcript

Easier to understand what NexoBrid is all about.
TAM $200 Million. Margins aligned with other products.
Home Run, in a year or two, investors would say, Epicel, oh yeah, how is that doing. I wonder if it even might get fast track FDA approval.

[manisero66]

Premarket is being done by junior trading. Excellent future for longs with the new acquisition.

[TVDirector]

Still taking quite the beating premarket

I suppose a miss is a miss, even with respectable guidance and so forth.

Onto next Q-

[realfast95]

The miss was because of Epicel. Excluding Epicel, they beat by $100k.
Increaded guidance slightly.

[realfast95]

Vericel EPS in-line, misses on revenue
May 7, 2019 7:03 AM ET|About: Vericel Corporation (VCEL)|By: Mamta Mayani, SA News Editor

Vericel (NASDAQ:VCEL): Q1 GAAP EPS of -$0.07 in-line.

Revenue of $21.81M (+21.0% Y/Y) misses by $0.7M.

Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today reported financial results for the first quarter ended March 31, 2019, and recent business highlights.

First Quarter 2019 Financial Highlights

Total net product revenues increased 21% to $21.8 million compared to $18.0 million in the first quarter of 2018;
Gross margins of 60% compared to gross margins of 57% in the first quarter of 2018;
Net loss of $2.8 million, or $0.07 per share, compared to $7.7 million, or $0.21 per share, in the first quarter of 2018;
Non-GAAP adjusted EBITDA loss of $0.4 million compared to a loss of $2.6 million in the first quarter of 2018;
As of March 31, 2019, the company had $84.1 million in cash and short-term investments compared to $82.9 million as of December 31, 2018; and
Full year 2019 revenue guidance for MACI® and Epicel® raised to $110 to $114 million compared to previous full year revenue guidance of $108 million to $112 million.

Recent Business Highlights
During and since the first quarter of 2019, the company:

Announced an exclusive license agreement with MediWound Ltd. for North American rights to NexoBrid®, a biological orphan product for debridement of thermal burns;
Deployed the expanded MACI sales force, which increased from 40 to 48 territories; and
Reported publication of outcomes data from 954 burn patients treated with Epicel in the Journal of Burn Care and Research.

“We delivered another solid quarter of performance and the MACI sales force continues to increase its productivity even as we add new representatives, which speaks to the quality of our sales representatives as well as the demand for MACI,” said Nick Colangelo, president and CEO of Vericel. “Based on the strong underlying indicators of growth for the rest of the year we have raised our full year 2019 revenue guidance. Moreover, we believe that the addition of NexoBrid significantly expands our burn care target addressable market and will enable us to build a second significant commercial franchise to go along with our cartilage repair franchise, thereby enhancing the long-term growth profile of the company.”

First Quarter 2019 Results
Total net product revenues for the quarter ended March 31, 2019 increased 21% to $21.8 million compared to $18.0 million in the first quarter of 2018. Total net product revenues for the quarter included $16.6 million of MACI® (autologous cultured chondrocytes on porcine collagen membrane) net revenue and $5.2 million of Epicel® (cultured epidermal autografts) net revenue, compared to $12.1 million of MACI net revenue and $6.0 million of Epicel net revenue, respectively, in the first quarter of 2018.

Gross profit for the quarter ended March 31, 2019 was $13.2 million, or 60% of net revenues, compared to $10.4 million, or 57% of net revenues, for the first quarter of 2018.

Total operating expenses for the quarter ended March 31, 2019 were $16.5 million compared to $14.7 million for the same period in 2018. The increase in operating expenses was primarily due to a $1.2 million increase in stock-based compensation, an incremental $0.6 million in MACI sales force expenses as a result of the sales force expansion in the second quarter of 2018, and a $0.6 million increase in selling expenses and patient reimbursement support services.

Vericel’s net loss for the quarter ended March 31, 2019 was $2.8 million, or $0.07 per share, compared to $7.7 million, or $0.21 per share, for the first quarter of 2018.

Non-GAAP adjusted EBITDA loss was $0.4 million for the quarter ended March 31, 2019 compared to a loss of $2.6 million in the first quarter of 2018. See table reconciling non-GAAP measures for more details.

As of March 31, 2019, the company had $84.1 million in cash and short-term investments compared to $82.9 million as of December 31, 2018.

Full Year 2019 Financial Guidance
The company now expects total MACI and Epicel net product revenues for the full year 2019 to be in the range of $110 to $114 million, compared to the previous full year revenue guidance of $108 to $112 million.

[realfast95]

MediWound Enters into Exclusive License Agreement with Vericel for Commercial Rights to NexoBrid in N. America; MediWound to Receive Upfront Payment of $17.5M, $7.5M on U.S. BLA Approval, Up to $125M in Sales Milestones
4:26 am ET May 7, 2019 (Benzinga) Print

MediWound Ltd. (Nasdaq: MDWD) today announced that it has entered into exclusive license and supply agreements with Vericel Corporation (NASDAQ: VCEL) to commercialize NexoBrid in North America (NA). NexoBrid is a topically-administered biologic product that removes eschar in patients with deep partial and full-thickness thermal burns, which is approved in the European Union and other international markets. The pivotal U.S. phase 3 DETECT clinical study met its primary and all secondary endpoints, and the submission of the Biological License Application (BLA) to the U.S. Food and Drug Administration (FDA) is planned for the fourth quarter of 2019.

Pursuant to the agreements, MediWound will be responsible for the development activities of NexoBrid to obtain U.S. marketing approval from the FDA, supported and funded by BARDA, as well as the manufacture and supply of NexoBrid. MediWound retains the commercial rights to NexoBrid in all non-North American territories. Under the terms of the license agreement, Vericel will make an upfront payment to MediWound of $17.5 million, with an additional $7.5 million payment contingent upon U.S. BLA approval and up to $125 million in payments contingent upon meeting certain annual sales milestones. Vericel will also pay MediWound tiered royalties on net sales ranging from high single-digit to low double-digit percentages, a split of gross profits on committed BARDA procurement orders and a double-digit royalty on any additional future BARDA purchases of NexoBrid. Under the terms of the supply agreement, Vericel will procure NexoBrid from MediWound at a transfer price of cost plus a fixed margin percentage.

"We are very pleased with this collaboration with Vericel, a company with significant expertise and commercial infrastructure in place in the burn care community. This deal is strategic for both parties and we believe Vericel is the ideal commercial partner to drive market penetration to maximize the medical and commercial potential of NexoBrid in North America," stated Stephen T. Wills, MediWound's Chairman.

Mr. Wills continued, "As our comprehensive strategic process evolved, we concluded that licensing NexoBrid was the right first step towards monetizing our development programs and create near-term value. The cash flow from this transaction provides us with the funds to significantly advance EscharEx, our topical biologic drug candidate for the debridement of chronic and other hard-to-heal wounds, through BLA filing. Based on the multiple indications of interest EscharEx received during the strategic process, we believe that EscharEx has the potential to have a meaningful impact on wound care treatment and become a dominant debriding agent in the marketplace. While we will always assess potential strategic opportunities, this licensing deal gives us flexibility regarding the timing to monetize EscharEx and maximize shareholder value."

Sharon Malka, MediWound's Chief Executive Officer, commented, "The collaboration with Vericel, an active player with commercial presence in the U.S. burn care market, further validates the clinical and commercial value of NexoBrid as a new paradigm in burn care management. We have an upcoming pre-BLA meeting scheduled with the FDA, and subject to FDA concurrence, plan to file the BLA later this year. Regarding NexoBrid in non-North American territories, we will be directing our attention towards greater market penetration by adding new distributors and obtaining additional marketing approvals. Importantly, we believe that the proceeds generated from this collaboration, combined with existing cash on hand, will allow us to advance and optimize the ongoing development of EscharEx through BLA filing. We expect to commence the next step of the EscharEx clinical development program in the second quarter of 2019."

"We are very pleased with this agreement to commercialize NexoBrid in North America," stated Nick Colangelo, President and Chief Executive Officer of Vericel. "We are excited to collaborate with the MediWound team to obtain FDA approval for NexoBrid and integrate this innovative and critical product into our burn product portfolio. We believe that NexoBrid is an excellent strategic fit that can help increase penetration of Epicel and enable us to treat additional patients and capture a larger share of the North American burn care market."

MediWound announced in January 2019 that it met its primary and all secondary endpoints in its pivotal U.S. Phase 3 DETECT clinical study with NexoBrid to treat patients with deep partial thickness and full thickness thermal burns. DETECT was a prospective, controlled, multi-center, multi-national assessor-blinded Phase 3 study in 175 patients at 44 burn centers randomized to either NexoBrid, Standard of Care, or the Gel Vehicle placebo at a ratio of 3:3:1, with 12- and 24-month long-term safety follow-up. The study met its primary endpoint of complete eschar removal, as well as secondary endpoints of reduction in the need for surgical eschar removal (surgical burden), earlier eschar removal, and blood loss.

The BLA currently is targeted for submission to the FDA in the fourth quarter of 2019 based on the acute primary, secondary and safety data, with the analysis of the twelve-month safety follow-up data submitted during the BLA review and the twenty-four-month safety follow-up data submitted as BLA supplements, subject to FDA concurrence at a pre-BLA meeting planned for the second quarter of 2019.

Funding and support for NexoBrid development costs required to obtain marketing approval in the U.S., including the ongoing DETECT study and a Phase 3 pediatric (CIDS) study is provided by BARDA, under the Assistant Secretary for Preparedness and Response (ASPR), within the U.S. Department of Health and Human Services (HHS), under ongoing USG Contract No. HHSO100201500035C and HHSO100201800023C. The contracts also include a $16.5 million commitment for procurement of NexoBrid contingent upon FDA eligibility for use in an emergency or FDA marketing approval. The contract provides an option to fund up to $50 million for additional NexoBrid procurement

Moelis & Company acted as financial advisor to MediWound.

[realfast95]

Anticipation before earnings in the morning

[realfast95]

crossroads

[TVDirector]

shall I remove the rock to mention today's debacle?

nahhhhhh

don't take yourself so seriously, lunacy.

[TVDirector]

very nice to see an up day!

been pretty rocky lately...
a nice up day is exactly what's needed!

back under my rock now...

[realfast95]

Welcome @Briefingcom Followers!
twitter
$VCEL: Correction: Vericel did not appoint new CEO and original post has been removed (16.26)
Obsidian Therapeutics, a biotechnology company developing cell-based therapeutics with controllable operating systems, today announced the appointment of Paul K. Wotton, Ph.D., as Chief Executive Officer. He succeeds Michael Gilman, Ph.D., who will focus on Arrakis Therapeutics and continue to serve on Obsidian's Board of Directors.

[Lunacy_John Galt]

You certainly have a pattern of crawling out of your hole to chime in on down days don’t ya?

[TVDirector]

16.26!is quite the walking down!

Even with healthcare nervousness, you gotta wonder about a 12+% drop.

[silvergun]

Looks cheap here close to $16
VCEL should def see $25+ over next few months. Can be a $35++ stock within 1-2 yrs

[realfast95]

no news. they walked it down with weak ibb index.
option guys who sold calls at 17.5 cleaned up.

[TVDirector]

What’s with the steep plunge this am?
Haven’t seen anything post-Needham.
Seemed like footing was being established, but a real race to the bottom in the first 30 minutes of trading today.

[realfast95]

Competitor HSGX officially dead.

Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics
7:05 am ET April 8, 2019 (Globe Newswire) Print

Immediately following the closing of the transaction, the former stockholders of Ocugen will hold approximately 90% of the outstanding shares of common stock of the combined company and the current Histogenics stockholders will retain an ownership interest representing approximately 10% of the outstanding shares of common stock of the combined company, subject to certain adjustments as described in the merger agreement of up to an additional 5% ownership for the current Histogenics stockholders based on Histogenics' cash at the closing of the proposed merger, including proceeds from sale of the assets underlying Histogenics' NeoCart product in connection with the closing.

Upon closing of the transaction, Histogenics will be renamed Ocugen, Inc. and will be headquartered in Malvern, Pennsylvania under the leadership of Ocugen's current management team. Dr. Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, will continue as the Chairman and CEO of the combined company. Susan L. Drexler, C.P.A., M.B.A. will be the interim Chief Financial Officer and Dan Jorgensen, M.D., M.P.H., M.B.A., will be the Chief Medical Officer. No Histogenics employees will remain employed by the combined company.

[realfast95]

intra day 17.12 down .72

1 gap to fill


up Nov-06-2018
12.15 to 14.1

[TVDirector]

ouch- down over another buck since I wrote that!

ugly territory for sure.

[TVDirector]

18.83- low vol/interest + higher short holdings could make this a real bummer of a stretch for long investors.

hoping that some unexpected good news appears and reverses this trend.
and sooner than later

[Lunacy_John Galt]

The vast majority of the time the company covers the cost of training. On rare occasion the physicians or hospital will pay for it. In Vericel’s case, the training is very straightforward and can be done online or at these conferences, in addition to traditional training courses.

[realfast95]

Las Vegas AAOS convention
MACi booth. From a user Ortho91 on Stocktwits
American Academy of Orthopaedic Surgeons

(Doctors buy stocks too)

[manisero66]

Your suggestion that "surgeons study for the sake of it" leads me to another question. Who pays for the training of this specialists Vericel or they surgeons themselves?

[Lunacy_John Galt]

Of the 900 trained surgeons, many of them will never treat...that's just how it goes in the med device world. However, I'm not seeing the point/concern you're trying to make?

[manisero66]

And 3.000 patients divided by 900 surgeons makes 3,33 surgeries a year per surgeon. Too many cooks in the kitchen for me.

[NE_Gainz]

Where’s that clown Smart / Wendy / Twisty ? Hope that trip to Germany worked out for yah. While you’ve been making up FUD VCEL has climbed all the way to the TOP! Dig it ?

[realfast95]

short interest

2/28/2019 5,147,553
2/15/2019 4,928,668

[Topgun21]

$VCEL looking tasty!!!!

Been a GREAT RUN over last 18 months!!